Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valaciclovir to prevent CMV-mediated immune modulation in ANCA-associated vasculitis
2012-001970-28Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Oct 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of valaciclovir in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and cytomegalovirus disease (CMV), sponsored by University of Birmingham. Primary endpoint: CMV reactivation rate. Status: unknown.
02
Drugs
valaciclovir
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2012-001970-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001970-28.